Valuation · US stocks
Viridian Therapeutics, Inc. (VRDN) valuation
As of 2026-11-18, Viridian Therapeutics, Inc. trades at $30.12, above the highest fair-value bound of its 1, 3 and 5-year windows.
- Price
- $30.12
- Day change
- +0.20%
- Market cap
- $3.24B
- Sector
- Pharmaceuticals: Major
- Valuation
- Above band
- As of
- 2026-11-18
Other Pharmaceuticals: Major stocks
| Stock | Price | Market cap | Valuation |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,382.31 | $1.27T | Fair |
| Johnson & Johnson JNJ | $272.72 | $646.92B | Above band |
| Merck & Co., Inc. MRK | $137.75 | $366.28B | Above band |
| AstraZeneca PLC AZN | $178.77 | $289.48B | Fair |
| Novo Nordisk A/S Sponsored ADR Class B NVO | $39.45 | $176.43B | Fair |
| Pfizer Inc. PFE | $28.06 | $166.61B | Above band |
| Bristol-Myers Squibb Company BMY | $59.56 | $132.14B | Fair |
| Vertex Pharmaceuticals Incorporated VRTX | $536.45 | $132.00B | Fair |
| Regeneron Pharmaceuticals, Inc. REGN | $945.53 | $83.42B | High |
| Royalty Pharma Plc Class A RPRX | $68.67 | $39.04B | Above band |
| Biogen Inc. BIIB | $251.41 | $37.49B | Above band |
| Zoetis, Inc. Class A ZTS | $85.57 | $30.40B | Below band |
How the valuation band works
Wave Radar estimates a fair-value range from each company's earnings, book value and its own historical P/E and P/B over 1, 3 and 5-year windows. The 1-year window gives the tight range; the widest bounds across all windows give the loose one. "Low" and "High" mean the price has left the tight range; "Below band" and "Above band" mean it has left even the widest one.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.